Back

Use and associations with mortality/morbidity of guideline-directed medical therapy use in heart failure with improved ejection fraction: a PS-matched analysis from the swedish heart failure registry

1 September 2024 (13:00 - 13:50)
Organised by: Logo
Congress Presentation Part of: Optimisation of heart failure treatment Heart Failure with Reduced Ejection Fraction (HFrEF) ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Christian Basile

Karolinska Institute, Stockholm (Sweden)

8 More presentations in this session

Presentation thumbnail
Up-titration of Guideline Directed Medical Therapy (GDMT) and the occurrence of side effects in Heart Failure with reduced Ejection Fraction (HFrEF)
Doctor N. Panagiotides (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Visit-to-visit changes in heart rate in heart failure: a pooled participant-level analysis of the PARADIGM-HF and PARAGON-HF trials
Doctor H. Lu (Lausanne, CH)
Abstract Slides Video
Presentation thumbnail
SGLT2 inhibitors are associated with development of heart failure with improved ejection fraction
Doctor X. Wang (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Survival benefit of guideline-directed medical therapy in elderly patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis
Doctor E. Tan (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Differences in the optimization of pharmacological treatment in patients with heart failure and reduced ejection fraction and advanced chronic kidney disease.
Doctor A. Recio Mayoral (Seville, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Optimisation of heart failure treatment

The Event

Event poster

ESC Congress 2024

1 September 2024 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Can we withdraw heart failure drugs in HFimpEF, HFrecHF, and HFremEF?
thumbnail
Congress Presentation
Improvements in medical therapy and prognosis for patients with HFrEF following the 2021 ESC HF Guidelines: a nationwide registry study
thumbnail
Congress Presentation
Safety and long-term outcomes of heart failure drug minimization in patients with improved ejection fraction: SLIM-HF study

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources